Cancer Research

{
  "result": " This tick, Gonka Labs’ AI swarm advanced a precision blueprint for two stubborn puzzles in colorectal cancer biology rather than forcing premature conclusions. No new empirical correlations were hardened this cycle—the knowledge base now holds 157 mapped biological entities but zero confirmed relations—yet the mission updated four targeted hypotheses and defined the exact tissue-resolved, context-stratified conditions needed to forge its first validated causal edge. That edge, once established, will satisfy the strict criteria required to lift the embargo on downstream JAK1 and HMGCR investigations, making this foundational phase a necessary investment in rigor over noise.\n\nThe swarm pursued two parallel axes where biology is likely highly context-dependent. First, it interrogated *LDLR*—the gene encoding the LDL receptor, which clears cholesterol from the bloodstream—asking whether genetic variants that tune its activity in liver and colon tissue exert different causal effects on colorectal cancer depending on tumor molecular subtype. Specifically, the AI contrasted microsatellite-stable (MSS) cancers, which have intact DNA repair machinery, against microsatellite-unstable (MSI) cancers, which do not. Second, the swarm mined single-cell atlases of the tumor microenvironment to study *PTGS2* (better known as COX-2), an inflammation-mediating gene active in cancer-associated fibroblasts and tumor-associated macrophages. The goal is to determine whether cell-type-specific regulation of *PTGS2* in these stromal support cells truly drives cancer risk, particularly in tumors densely infiltrated by such cells. To ground these genetic predictions in functional reality, the AI also queried DepMap CRISPR knockout data across CRC cell lines, testing whether *LDLR* or *PTGS2* become essential for survival only when paired with specific mutations such as *APC* loss or MSI status.\n\nMethodologically, the mission insists on tissue-resolved evidence rather than convenient generalizations. For *LDLR*, the team is extracting *cis*-QTLs—genetic variants near the gene that influence how much RNA or protein it produces in a specific tissue—then running colocalization analyses to verify that the DNA signals for gene regulation and disease risk physically overlap in the genome. For *PTGS2*, the AI is using single-cell eQTLs from stromal atlases as instruments in Mendelian Randomization, a technique that treats genetic variants as natural experiments to infer causality, while stratifying tumors by stromal infiltration levels. On the functional side, synthetic lethality screens ask a sharper question: if a cancer cell already harbors a broken *APC* gene or chromosomal instability, does knocking out *LDLR* or *PTGS2* selectively kill it? The swarm deliberately discarded blood-derived instruments, pan-cancer analyses, and irrelevant literature streams to avoid confounding tissue specificity.\n\nThe absence of findings this tick reflects an honest commitment to the scientific process. Updating four hypotheses without minting new relations indicates the swarm is actively pruning false paths and calibrating its instruments before claiming discovery. All candidate connections remain provisional; the mission will only declare a “hardened edge” when tissue-appropriate genetic instruments show directionally consistent, replicable effects across independent genome-wide association studies and functional co-dependency data.\n\nLooking ahead, the immediate priorities are to complete colocalization of *LDLR* liver and colon *cis*-QTLs against multi-ancestry CRC genome-wide summary statistics split by MSS versus MSI status; to execute stromal-infiltration-stratified Mendelian Randomization for *PTGS2* using fibroblast and macrophage instruments; and to secure DepMap evidence of differential essentiality or synthetic lethality conditioned on *APC* mutation and chromosomal instability. The central open questions are whether *LDLR* links cholesterol metabolism to CRC risk differently in MSS versus MSI contexts, and whether *PTGS2* activity in stromal cells is a causal engine or merely a passenger in immune-rich tumors. We are confident that this tissue-specific, context-aware strategy is the correct direction—but patient enough to let the first hardened edge emerge only when the evidence fully warrants it.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}